Zacks Investment Research on MSN
REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug
Replimune Group’s REPL share price tumbled 54.2% over the past three months. The massive setback was observed after the FDA issued a complete response letter (CRL) in July, against the biologics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback